PHARMACOECONOMIC EVALUATION OF ABIRATERONE ACETATE VERSUS CABAZITAXEL IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN KAZAKHSTAN

被引：1
|
作者：
Kostyuk, A. [1 ]
Almadiyeva, A. [1 ]
机构：
[1] Natl Ctr Hlth Dev, Astana, Kazakhstan
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.513
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A412 / A412
页数：1
相关论文
共 50 条
  • [31] Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer
    Scott, Lesley J.
    Yang, Lily P. H.
    Lyseng-Williamson, Katherine A.
    [J]. DRUGS & AGING, 2012, 29 (03) : 243 - 248
  • [32] Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
    Rauch, Simon
    Fong, Dominic
    Morra, Elisa
    Maines, Francesca
    Caffo, Orazio
    Spizzo, Gilbert
    [J]. PROSTATE INTERNATIONAL, 2016, 4 (02) : 54 - 55
  • [33] Abiraterone AcetateIn Metastatic Castration-Resistant Prostate Cancer
    Lily P. H. Yang
    [J]. Drugs, 2011, 71 : 2067 - 2077
  • [34] Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
    Zobniw, Chrystia M.
    Causebrook, Alanna
    Fong, Mei Ka
    [J]. RESEARCH AND REPORTS IN UROLOGY, 2014, 6 : 97 - 105
  • [35] PHARMACOECONOMIC ANALYSIS OF ENZALUTAMIDE AND ABIRATERONE FOR TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Avxentyev, N. A.
    Frolov, M.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
  • [36] Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study
    Sternberg, Cora N.
    Castellano, Daniel
    de Bono, Johann
    Fizazi, Karim
    Tombal, Bertrand
    Wuelfing, Christian
    Kramer, Gero
    Eymard, Jean-Christophe
    Bamias, Aristotelis
    Carles, Joan
    Iacovelli, Roberto
    Melichar, Bohuslav
    Sverrisdottir, Asgerdur
    Theodore, Christine
    Feyerabend, Susan
    Helissey, Carole
    Poole, Elizabeth M.
    Ozatilgan, Ayse
    Geffriaud-Ricouard, Christine
    de Wit, Ronald
    [J]. EUROPEAN UROLOGY, 2021, 80 (04) : 497 - 506
  • [37] The perennial natural history of castration-resistant prostate cancer in the patient treated with docetaxel, cabazitaxel and abiraterone acetate
    Wrona, Anna
    Senkus-Konefka, Elzbieta
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : C12 - C15
  • [38] ABIRATERONE ACETATE: PROSPECTIVE EVALUATION OF THE CARDIOVASCULAR SAFETY PROFILE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
    Ruatta, Fiorella
    Prati, Veronica
    Aversa, Caterina
    Gernone, Angela
    Galizia, Danilo
    Bonzano, Alessandro
    Torino, Sofia
    Nuzzolese, Imperia
    Marandino, Laura
    Aglietta, Massimo
    Ortega, Cinzia
    [J]. ANTICANCER RESEARCH, 2016, 36 (05) : 2615 - 2615
  • [39] Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer
    Scott, Lesley J.
    [J]. DRUGS, 2017, 77 (14) : 1565 - 1576
  • [40] Treatment of metastatic castration-resistant prostate cancer. Drug interaction potentials of abiraterone acetate and enzalutamide
    Lipp, H-P.
    Miller, K.
    [J]. UROLOGE, 2016, 55 (06): : 766 - 771
12345